State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, China.
Liver Int. 2022 Dec;42(12):2791-2799. doi: 10.1111/liv.15421. Epub 2022 Sep 19.
Cirrhosis is a major public health issue worldwide with significant morbidity and mortality. We aimed to explore the time series associations between varying levels of risk factors and cirrhosis prevalence and predict the cirrhosis prevalence under alternative scenarios to consolidate evidence for further intervention plans.
We collected data of cirrhosis and its risk factors from 1990 to 2019 across 178 countries and used a generalized linear mixed model to explore the time series associations between cirrhosis and risk factors. We simulated scenarios with varying levels of risk factors and investigated benefits gained from the control of risk factors compared with the status quo.
The global cirrhosis prevalence varied geographically, with the highest observed in East and Southeast Asia, mainly due to high hepatitis prevalence. Our study revealed that each 1% increase in prevalence of hepatitis B and C, cirrhosis prevalence would correspondingly increase 0.028% and 0.288%. There would be approximately 392.15 million fewer cirrhosis patients if the goals of a 65% reduction in prevalence of hepatitis and a 10% reduction in alcohol consumption were achieved.
Given that cirrhosis prevalence has different risk factors depending on geography, it is important to identify an appropriate set of interventions for cirrhosis that are adapted to the epidemiological situation in a specific country. Interventions targeting hepatitis may have a significant impact on global cirrhosis prevalence, therefore, the adoption of specific interventions for hepatitis in high-burden regions and high-risk groups is warranted to lower the global burden of cirrhosis.
肝硬化是全球范围内的一个主要公共卫生问题,具有较高的发病率和死亡率。本研究旨在探讨不同水平的危险因素与肝硬化患病率之间的时间序列关联,并预测在不同情景下的肝硬化患病率,以整合证据,为进一步的干预计划提供依据。
我们收集了 1990 年至 2019 年 178 个国家的肝硬化及其危险因素数据,采用广义线性混合模型探讨肝硬化与危险因素之间的时间序列关联。我们模拟了不同水平的危险因素情景,并评估了与现状相比,控制危险因素所能带来的收益。
全球肝硬化患病率存在地域差异,东亚和东南亚地区的患病率最高,主要归因于乙型肝炎和丙型肝炎的高流行率。我们的研究发现,乙型肝炎和丙型肝炎的流行率每增加 1%,肝硬化的流行率将相应增加 0.028%和 0.288%。如果实现乙型肝炎流行率降低 65%和饮酒量减少 10%的目标,全球肝硬化患者数量将减少约 3921.5 万。
鉴于肝硬化的患病率因地理位置而异,确定一套适合特定国家流行病学情况的肝硬化干预措施非常重要。针对肝炎的干预措施可能对全球肝硬化患病率产生重大影响,因此,在高负担地区和高风险人群中采取特定的肝炎干预措施,以降低全球肝硬化负担是必要的。